Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting the β-catenin/TCF transcriptional complex in the treatment of multiple myeloma

24 Apr 2007

Abstract excerpt

Multiple myeloma (MM) is an invariably fatal form of cancer characterized by clonal proliferation of malignant plasma cells in the bone marrow. The canonical Wnt signaling pathway is activated in MM cells through constitutively active beta-catenin, a messenger molecule relevant to growth, survival, and migration of MM cells. The identification of a number of small molecular compounds, such as PKF115-584, which...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Peptidase Inhibition and Analysis
Share to Ubiquitin and proteasome pathways
Share to Wnt/β-catenin signaling in development and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17452641
DOI: 10.1073/pnas.0610299104

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting the β-catenin/TCF transcriptional complex in the treatment of multiple myelomaPMID 17452641Read ↗

AV-65, a novel Wnt/β-catenin signal inhibitor, successfully suppresses progression of multiple myeloma in a mouse modelSemantic proximity Read ↗

Aurora kinase A is a target of Wnt/β-catenin involved in multiple myeloma disease progressionSemantic proximity Read ↗

Crosstalk between microRNA30a/b/c/d/e-5p and the Canonical Wnt Pathway: Implications for Multiple Myeloma therapySemantic proximity Read ↗

miR-30-5p Functions as a Tumor Suppressor and Novel Therapeutic Tool by Targeting the Oncogenic Wnt/β-Catenin/BCL9 PathwaySemantic proximity Read ↗

GSK3-mediated MAF phosphorylation in multiple myeloma as a potential therapeutic targetSemantic proximity Read ↗

MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myelomaSemantic proximity Read ↗

Loss of CYLD expression unleashes Wnt signaling in multiple myeloma and is associated with aggressive diseaseSemantic proximity Read ↗

The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity.Semantic proximity Read ↗

A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expressionSemantic proximity Read ↗

MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myelomaSemantic proximity Read ↗

Downregulation of miRNA‑15a and miRNA‑16 promote tumor proliferation in multiple myeloma by increasing CABIN1 expressionSemantic proximity Read ↗

A dominant-negative F-box deleted mutant of E3 ubiquitin ligase, β-TrCP1/FWD1, markedly reduces myeloma cell growth and survival in mice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.